Hemispherx Biopharma Inc. CEO Thomas Equels told BioWorld Today that the approval in the Argentine Republic of rintatolimod for severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is “the opening of a door” to the rest of the world, which is waking up to the reality of the disease as research picks up momentum.